An angiotensin-converting enzyme inhibitor, zofenopril, prevents renal ischemia/reperfusion injury in rats

Annals of Clinical and Laboratory Science

Volumn 36, Issue 3, 2006, Pages 326-332

  Altunoluk, Bulent ^a   Soylemez, Haluk ^b   Oguz, Fatih ^b   Turkmen, Emine ^b   Fadillioglu, Ersin ^c  

^a Division of Urology   (Turkey)

^b INONU UNIVERSITY   (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Antioxidants; Kidney ischemia reperfusion; Oxidative stress; Zofenopril

Indexed keywords

CARBONYL DERIVATIVE; CATALASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MALONALDEHYDE; MYELOPEROXIDASE; NITRIC OXIDE; SUPEROXIDE DISMUTASE; XANTHINE OXIDASE; ZOFENOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CELL SWELLING; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY PERFUSION; KIDNEY TUBULE EPITHELIUM; LIPID PEROXIDATION; MORPHOLOGY; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN DETERMINATION; RAT; RENAL PROTECTION; REPERFUSION INJURY; SCORING SYSTEM;

ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; FEMALE; KIDNEY; KIDNEY TUBULES; OXIDATIVE STRESS; RATS; RENAL CIRCULATION; REPERFUSION INJURY; STATISTICS, NONPARAMETRIC;

ANIMALIA;

EID: 33748258361     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Cagli K, Bagci C, Gulec M, Cengiz B, Akyol O, Sari I, Cavdar S, Pence S, Dinckan H. In vivo effects of caffeic acid phenethyl ester on myocardial ischemia-reperfusion injury and apoptotic changes in rats. Ann Clin Lab Sci 2005;35:440-448.
2. Erdogan H, Fadillioglu E, Yagmurca M, Ucar M, Irmak MK. Protein oxidation and lipid peroxidation after renal ischemia/reperfusion injury: protective effects of erdosteine and nacetylcysteine. Urol Res 2006;34:41-46.
3. Sekhon CS, Sekhon BK, Singh I, Orak JK, Singh AK. Attenuation of renal ischemia/reperfusion injury by a triple drug combination therapy. J Nephrol 2003;16:63-74.
4. Irmak MK, Koltuksuz U, Kutlu NO, Yagmurca M, Ozyurt H, Karaman A, Akyol O. The effect of caffeic acid phenethyl ester on ischemia-reperfusion injury in comparison with alpha-tocopherol in rat kidneys. Urol Res 2001;29:190-193.
5. Giovannini L, Migliori M, Longoni BM, Das DK, Bertelli AA, Panichi V, Filippi C, Bertelli A . Resveratrol, a polyphenol found in wine, reduces ischemia reperfusion injury in rat kidneys. J Cardiovasc Pharmacol 2001;37: 262-270.
6. Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, Ozyurt H, Savas HA. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/ antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:995-1005.
7. Winrow VR, Winyard PG, Morris CJ, Blake DR. Free radicals in inflammation: second messengers and mediators of tissue destruction. Br Med Bull 1993; 49:506-522.
8. Fadillioglu E, Oztas E, Erdogan H, Yagmurca M, Sogut S, Ucar M, Irmak, MK. Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats. J Appl Toxicol 2004;24:47-52.
9. Kettle AJ, Winterbourn CC. Myeloperoxidase: a key regulator of neutrophil oxidant production. Redox Report 1997;3:3-15.
10. Arnhold J, Osipov AN, Spalteholz H, Panasenko OM, Schiller J. Effects of hypochlorous acid on unsaturated phosphatidylcholines. Free Radic Biol Med 2001;31: 1111-1119.
11. de Nigris F, D'Armiento FP, Somma P, Casini A, Andreini I, Sarlo F, Mansueto G, De Rosa G, Bonaduce D, Condorelli M, Napoli C. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 2001;81:107-116.
12. Sun Y, Mendelsohn FA. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration of zofenopril, captopril, and lisinopril. J Cardiovasc Pharmacol 1991;18:478-486.
13. Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol 2001;414:71-78.
14. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opin Pharmacother 2004;5:1965-1977.
15. Mak IT, Freedman AM, Dickens BF, Weglicki WB. Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 1990;40:2169-2175.
16. Lowry O, Rosenbraugh N, Farr L, Rondall R. Protein measurement with the Folin-phenol reagent. J Biol Chem 1951;183:265-275.
17. Aebi H. Catalase. In: Methods of Enzymatic Analysis (Bergmeyer HU, Ed), Academic Press, New York, 1974; pp 673-677.
18. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988;34:497-500.
19. Prajda N, Weber G. Malign transformation-linked imbalance: decreased XO activity in hepatomas. FEBS Lett 1975;59:245-249.
20. Wei H, Frenkel K. Relationship of oxidative events and DNA oxidation in SENCAR mice to in vivo promoting activity of phorbol ester-type tumor promoters. Carcinogenesis 1993;14:1195-1201.
21. Cortas NK, Wakid NW Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method. Clin Chem 1990;36:1440-1443.
22. Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. In: Methods in Enzymology, vol 186 (Packer L, Glazer AN, Eds), Academic Press, San Diego, 1990; pp 407-421.
23. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stantman ER. Determination of carbonyl content in oxidatively modified proteins. In: Methods in Enzymology, vol 186 (Packer L, Glazer AN, Eds), Academic Press, San Diego, 1990; pp 464-478.
24. Matsuyama M, Yoshimura R, Hase T, Kawahito Y, Sano H, Nakatani T. Study of cyclooxygenase-2 in renal ischemia-reperfusion injury. Transplant Proc 2005;37: 370-372.
25. Hernandez-Presa MA, Bustos C, Ortego R, Tunon J, Ortega L, Egido J. ACE inhibitor quinapril reduces the arterial expression of NF-kappaB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol 1998;153:1825-1837.
26. Brovkovych V, Dobrucki LW, Brovkovych S, Dobrucki I, Kalinowski L, Kiechle F, Malinski T. Nitric oxide measurements during endotoxemia. Clin Chem 2001;47: 1068-1074.
27. Marzo A, Dal Bo L, Mazzucchelli P. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers. Arzneimittelforschung 2002;52:233-242.
28. Napoli C, Cicala C, D'Armiento FP, Roviezzo F, Somma P, de Nigris F, Zuliani P, Bucci M, Aleotti L, Casini A, Franconi F, Cirino G. Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in Watanabe heritable hyperlipidemic rabbits. Gen Pharmacol 1999;33:467-477.
29. Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ, Liguori A. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004;148:e5
30. Keidar S, Kaplan M, Hoffman A, Aviram M. Angiotensin II stimulates macrophage-mediated lipid peroxidation of LDL. Atherosclerosis 1995;115:201-215.
31. Cushman DW, Wang FL, Fung WC, Grover GJ, Harvey CM, Scalese RJ, Mitch SL, DeForrest JM. Comparison in vitro, ex vivo and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br J Clin Pharmacol 1989;28:115S-130S.
32. Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE, McMurray J. Antioxidant effects of angiotensin converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol 1992;19:330-340.
33. Scribner AW, Loscalzo J, Napoli C. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 2003; 482:95-99.
34. Rodriguez-Reynoso S, Leal C, Portilla-de Buen E, Castillo JC, Ramos-Solano F. Melatonin ameliorates renal ischemia/reperfusion injury. J Surg Res 2004;116: 242-247.
35. Igic R, Behnia R. Properties and distribution of angiotensin I converting enzyme. Curr Pharm Des 2003;9:697-706.